James Colvert, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,391 and has fallen 52.7% since, to $658 in 2025.
Across 260 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$886
- Coloplast$584
- Myriad Genetic Laboratories, Inc.$547
- Axonics, Inc.$362
- Healthtronics Stone Solutions, LLC$330
- Teleflex LLC$273
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,25996%
- Education$1964%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 53 | $886 |
| Coloplast | 28 | $584 |
| Myriad Genetic Laboratories, Inc. | 24 | $547 |
| Axonics, Inc. | 10 | $362 |
| Healthtronics Stone Solutions, LLC | 3 | $330 |
| Teleflex LLC | 9 | $273 |
| AbbVie(2 entities) | 17 | $264 |
| Sumitomo Pharma America, Inc. | 14 | $248 |
| Pfizer | 12 | $234 |
| Boston Scientific | 13 | $222 |
| Medtronic | 7 | $190 |
| Neotract Inc. | 10 | $186 |
| Accord Healthcare, Inc. | 9 | $148 |
| Procept Biorobotics Corporation | 4 | $145 |
| Endo Pharmaceuticals Inc. | 8 | $114 |
| Urovant Sciences Inc | 7 | $107 |
| Myovant Sciences Inc. | 5 | $102 |
| Verity Pharmaceuticals Inc. | 4 | $80 |
| Ambu Inc. | 1 | $53 |
| Clarus Therapeutics Inc. | 3 | $45 |
| Urogen Pharma, Inc. | 2 | $40 |
| Travere Therapeutics, Inc. | 2 | $34 |
| Laborie Medical Technologies Corp. | 2 | $33 |
| Johnson & Johnson | 2 | $28 |
| Convatec Inc. | 1 | $27 |
| Innovation Technologies Inc | 1 | $27 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Hollister Incorporated | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Immunitybio, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mobile Cryoblation Services$311
- Axonics$138
- myRisk$133
How this compares
$5,454 in reported general payments places this provider in the 55th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 528 | $296,520 |
| GemtesaVibegron | 36 | $26,874 |
| Potassium Citrate ErPotassium Citrate | 187 | $19,978 |
| Estradiol | 212 | $17,635 |
| Tamsulosin Hcl | 907 | $12,987 |
| Bethanechol Chloride | 166 | $11,548 |
| Solifenacin Succinate | 169 | $9,776 |
| Trimethoprim | 94 | $9,184 |
| Silodosin | 84 | $7,826 |
| Finasteride | 167 | $3,394 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 16 | $1,493 |
| Tolterodine Tartrate ErTolterodine Tartrate | 27 | $1,108 |
| Dutasteride | 34 | $1,060 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 24 | $790 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 11 | $567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $886 | $296,520528 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $248 | $26,87436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 145 urology providers in Oklahoma.
Other urology in Enid
- Jarrett KruskaEnid$6K
- Mohammad RamadanOklahoma City$207K
- Michael CooksonOklahoma City$132K
- Melanie KetchandjiTulsa$111K
- Kelly StrattonOklahoma City$62K
- Ashley BowenOklahoma City$32K
- Marc MilstenTulsa$29K
- Scott LitwillerTulsa$27K
- Sardar Mohammad Khan GalzieOklahoma City$25K
- Charles PritchardTulsa$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.